Ra­dio­phar­ma­ceu­ti­cals start­up Rayze­Bio sub­mits IPO pitch, fore­shad­ow­ing ex­pect­ed post-La­bor Day bump in biotech list­ings

A Phase III-stage ra­dio­phar­ma­ceu­ti­cals biotech has filed to go pub­lic a lit­tle over a week be­fore bankers and in­dus­try watch­ers ex­pect a slight post-La­bor Day bump in biotech IPO pitch­es.

Af­ter hav­ing raised $418 mil­lion pri­vate­ly, the San Diego start­up Rayze­Bio hopes to gain a spot on the Nas­daq and trade as “RYZB,” per an S-1 fil­ing from Thurs­day evening.

Rayze­Bio is like­ly one of a few drug de­vel­op­ers that will go pub­lic be­fore year’s end; Jor­dan Saxe, Nas­daq’s head of health­care list­ings, told End­points News last month that the ex­change an­tic­i­pates an­oth­er five to 10 be­fore New Year’s. Biotechs will look to pounce on any win­dow they can get in this mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER